- Home
- TRNR vs ENSC Comparison
TRNR vs ENSC Comparison
Compare TRNR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRNR
- ENSC
- Stock Information
- Founded
- TRNR 2017
- ENSC 2003
- Country
- TRNR United States
- ENSC United States
- Employees
- TRNR N/A
- ENSC N/A
- Industry
- TRNR Consumer Electronics/Appliances
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- TRNR Technology
- ENSC Health Care
- Exchange
- TRNR Nasdaq
- ENSC Nasdaq
- Market Cap
- TRNR 5.8M
- ENSC 5.2M
- IPO Year
- TRNR 2023
- ENSC N/A
- Fundamental
- Price
- TRNR $4.13
- ENSC $2.09
- Analyst Decision
- TRNR
- ENSC
- Analyst Count
- TRNR 0
- ENSC 0
- Target Price
- TRNR N/A
- ENSC N/A
- AVG Volume (30 Days)
- TRNR 92.3K
- ENSC 114.7K
- Earning Date
- TRNR 08-14-2025
- ENSC 08-13-2025
- Dividend Yield
- TRNR N/A
- ENSC N/A
- EPS Growth
- TRNR N/A
- ENSC N/A
- EPS
- TRNR N/A
- ENSC N/A
- Revenue
- TRNR $6,972,000.00
- ENSC $7,413,722.00
- Revenue This Year
- TRNR $578.14
- ENSC N/A
- Revenue Next Year
- TRNR $130.65
- ENSC $1,354.55
- P/E Ratio
- TRNR N/A
- ENSC N/A
- Revenue Growth
- TRNR 373.32
- ENSC 415.58
- 52 Week Low
- TRNR $3.61
- ENSC $1.62
- 52 Week High
- TRNR $536.30
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- TRNR 42.51
- ENSC 48.39
- Support Level
- TRNR $3.82
- ENSC $2.00
- Resistance Level
- TRNR $4.09
- ENSC $2.12
- Average True Range (ATR)
- TRNR 0.32
- ENSC 0.08
- MACD
- TRNR 0.09
- ENSC 0.00
- Stochastic Oscillator
- TRNR 51.49
- ENSC 59.88
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.